(Q43841288)

27 November 2017

title

Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study (English)

1 reference

27 November 2017

0 references

0 references

1 reference

David F Choy

6

0 references

Nicola A Hanania

1

object named as

Nicola A Hanania

1 reference

27 November 2017

10

William Busse

1 reference

27 November 2017

Sally Wenzel

2

1 reference

27 November 2017

Karin Rosén

3

1 reference

27 November 2017

Hsin-Ju Hsieh

4

1 reference

27 November 2017

Sofia Mosesova

5

1 reference

27 November 2017

Preeti Lal

7

1 reference

27 November 2017

Joseph R Arron

8

1 reference

27 November 2017

Jeffrey M Harris

9

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 April 2013

1 reference

American Journal of Respiratory and Critical Care Medicine

27 November 2017

published in

1 reference

27 November 2017

volume

187

1 reference

27 November 2017

issue

8

1 reference

27 November 2017

page(s)

804-811

1 reference

Asthma. From bronchoconstriction to airways inflammation and remodeling

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

Significant variability in response to inhaled corticosteroids for persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

Lessons learned from variation in response to therapy in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

Anti-IgE monoclonal antibody, omalizumab: a new treatment for allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

Narrative review: the role of Th2 immune pathway modulation in the treatment of severe asthma and its phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

T-helper type 2-driven inflammation defines major subphenotypes of asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

The cytokine network in asthma and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

Relationship between pretreatment specific IgE and the response to omalizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

Effect of omalizumab on peripheral blood eosinophilia in allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

Lebrikizumab treatment in adults with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

Standardization of Spirometry, 1994 Update. American Thoracic Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

Development of the Asthma Control Composite outcome measure to predict omalizumab response

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

Asthma outcomes: biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

Safety and tolerability of omalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201208-1414OC

10.1164/RCCM.201208-1414OC

21 January 2018

Identifiers

DOI

1 reference

27 November 2017

1 reference